HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $10 Price Target

Benzinga · 10/25 10:27
HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $10 price target.